<DOC>
	<DOCNO>NCT00724503</DOCNO>
	<brief_summary>This study randomize multi-center trial ass effect add SIRT , use SIR-Spheres microspheres , standard chemotherapy regimen FOLFOX first line therapy patient non-resectable liver metastasis primary colorectal adenocarcinoma . Treatment biologic agent bevacizumab , part standard care participate institution , allow within study discretion treat Investigator .</brief_summary>
	<brief_title>FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone Patients With Liver Mets From Primary Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Unequivocal measurable CT evidence liver metastases treatable surgical resection local ablation . Limited extrahepatic metastasis lung and/or lymph node permit ( Lung : 5 lesion total , &lt; 1 cm , 1 single lesion 1.7 cm ; Lymph nodules one single anatomic area ( pelvis , abdomen chest ) : number , &lt; 2 cm ) . Suitable either treatment regimen . Prior chemotherapy metastatic colorectal cancer allow . WHO performance status 01 . Adequate hematological , renal hepatic function . Age 18 year old . Willing able provide write informed consent . Life expectancy least 3 month without active treatment . Exclusion Criteria Evidence ascites , cirrhosis , portal hypertension , main portal venous tumor involvement thrombosis determine clinical radiologic assessment . Previous radiotherapy deliver upper abdomen . Nonmalignant disease would render patient unsuitable treatment accord protocol . Peripheral neuropathy &gt; grade 1 ( NCICTC ) . Dose limit toxicity previous adjuvant 5FU oxaliplatin chemotherapy . Prior nonadjuvant chemotherapy malignancy . Adjuvant chemotherapy colorectal cancer exclusion criterion provide complete 6 month entry study . Pregnant breastfeeding . Other active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>Colorectal carcinoma</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>SIR-Spheres microspheres</keyword>
	<keyword>yttrium-90</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>